Characterization of Clone 13, a Naturally Attenuated Avirulent Isolate of Rift Valley Fever Virus, which is Altered in the Small Segment *

Müller, Rolf; Saluzzo, J.F.; López, Nora; Dreier, Thomas M.; Turell, Michael J.; Smith, Jonathan; Bouloy, Michèle

doi:10.4269/ajtmh.1995.53.405

Cited by 251 publications

(235 citation statements)

References 0 publications

Supporting

Mentioning

227

Contrasting

Unclassified

Order By: Relevance

“…commun.). Another attenuated virus, clone 13, a naturally attenuated strain, is very promising regarding the preliminary results obtained in terms of immunogenicity and safety (Muller et al 1995).…”

Section: Control and Prevention Of Rvfmentioning

confidence: 99%

Molecular Epidemiology and Emergence of Rift Valley Fever

Sall

Zanotto

Vialat

et al. 1998

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

Section: Control and Prevention Of Rvfmentioning

confidence: 99%

Molecular Epidemiology and Emergence of Rift Valley Fever

Sall

Zanotto

Vialat

et al. 1998

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

“…MP12, a chemically attenuated virus derived from ZH548, an Egyptian wild-type isolate (Caplen et al 1985, Vialat et al 1997, is being evaluated as a potential vaccine for human and veterinary use. The immunogenicity and pathogenicity of these latter two candidate vaccines have been evaluated in various animal species (Muller et al 1995, Morrill et al 1997, and, although both vaccine candidates showed promising results, MP12 was reported to induce fetal malformations during the first trimester (Hunter et al 2002); however, a recent study reported the absence of fetal malformation in pregnant ewes inoculated with the virus (Morrill et al 2013). …”

mentioning

confidence: 99%

“…Strategies to develop RVFV vaccines include subunit (Schmaljohn et al 1989, Mandell et al 2010a, DNA (Spik et al 2006), viruslike particles (VLPs) , de Boer et al 2010, Kortekaas et al 2012, virus replicon particles (Kortekaas et al 2011, Dodd et al 2012, Oreshkova et al 2013), virus-vectored (Wallace et al 2006, Heise et al 2009) modified live vaccines, developed from recombinant viruses engineered using reverse genetics (Ikegami et al 2006, Bird et al 2008, Billecocq et al 2008, Habjan et al 2008, Bird et al 2011, live attenuated (Smithburn 1949, Caplen et al 1985, Muller et al 1995, Dungu et al 2010, Pittman 2012, Morrill et al 2013, and inactivated whole virus vaccines (Pittman et al 2000). Although subunit vaccines for RVFV are generally considered safe, and recently some progress has been made in their development, evaluation of immunogenicity and/or efficacy in a target species, sheep, has been performed for a few candidates (Kortekaas et al 2012, Oreshkova et al 2013).…”

mentioning

confidence: 99%

“…The formalin-inactivated wholevirus vaccines are safe but less immunogenic (Lubroth et al 2007). Clone 13, another live attenuated natural mutant, is now in commercial use in South Africa for the control of the disease in livestock (Muller et al 1995, Dungu et al 2010). MP12, a chemically attenuated virus derived from ZH548, an Egyptian wild-type isolate (Caplen et al 1985, Vialat et al 1997, is being evaluated as a potential vaccine for human and veterinary use.…”

mentioning

confidence: 99%

See 1 more Smart Citation

A Glycoprotein Subunit Vaccine Elicits a Strong Rift Valley Fever Virus Neutralizing Antibody Response in Sheep

Faburay

Lebedev²,

McVey³

et al. 2014

Vector-Borne and Zoonotic Diseases

View full text Add to dashboard Cite

Rift Valley fever virus (RVFV), a member of the Bunyaviridae family, is a mosquito-borne zoonotic pathogen that causes serious morbidity and mortality in livestock and humans. The recent spread of the virus beyond its traditional endemic boundaries in Africa to the Arabian Peninsula coupled with the presence of susceptible vectors in nonendemic countries has created increased interest in RVF vaccines. Subunit vaccines composed of specific virus proteins expressed in eukaryotic or prokaryotic expression systems are shown to elicit neutralizing antibodies in susceptible hosts. RVFV structural proteins, amino-terminus glycoprotein (Gn), and carboxylterminus glycoprotein (Gc), were expressed using a recombinant baculovirus expression system. The recombinant proteins were reconstituted as a GnGc subunit vaccine formulation and evaluated for immunogenicity in a target species, sheep. Six sheep were each immunized with a primary dose of 50 lg of each vaccine immunogen with the adjuvant montanide ISA25; at day 21, postvaccination, each animal received a second dose of the same vaccine. The vaccine induced a strong antibody response in all animals as determined by indirect enzyme-linked immunosorbent assay (ELISA). A plaque reduction neutralization test (PRNT 80 ) showed the primary dose of the vaccine was sufficient to elicit potentially protective virus neutralizing antibody titers ranging from 40 to 160, and the second vaccine dose boosted the titer to more than 1280. Furthermore, all animals tested positive for neutralizing antibodies at day 328 postvaccination. ELISA analysis using the recombinant nucleocapsid protein as a negative marker antigen indicated that the vaccine candidate is DIVA (differentiating infected from vaccinated animals) compatible and represents a promising vaccine platform for RVFV infection in susceptible species.

show abstract

“…Cells were infected in triplicate with RVFV clone 13 (40 PFU/well) 19 and incubated for 1.5 h at 37 °C. Virus was removed, 600 µL of Avicel overlay (300 µL of 2 × cell culture medium + 300 µL of 2.4% Avicel [FMC BioPolymer, Philadelphia, PA]) containing hit compounds (12.5 and 3.12 µM) was added, and the plate was incubated at 37 °C for 72 h. Then, the overlay was removed and the wells were washed with PBS.…”

Section: Plaque Reduction Neutralization Test (Prnt)mentioning

confidence: 99%

High-Throughput Screening Using a Whole-Cell Virus Replication Reporter Gene Assay to Identify Inhibitory Compounds against Rift Valley Fever Virus Infection

et al. 2016

View full text Add to dashboard Cite

Rift Valley fever virus (RVFV) is an emerging virus that causes serious illness in humans and livestock. There are no approved vaccines or treatments for humans. The purpose of the study was to identify inhibitory compounds of RVFV infection without any preconceived idea of the mechanism of action. A whole-cell-based high-throughput drug screening assay was developed to screen 28,437 small chemical compounds targeting RVFV infection. To accomplish both speed and robustness, a replication-competent NSs-deleted RVFV expressing a fluorescent reporter gene was developed. Inhibition of fluorescence intensity was quantified by spectrophotometry and related to virus infection in human lung epithelial cells (A549). Cell toxicity was assessed by the Resazurin cell viability assay. After primary screening, 641 compounds were identified that inhibited RVFV infection by ≥80%, with ≥50% cell viability at 50 µM concentration. These compounds were subjected to a second screening regarding dose-response profiles, and 63 compounds with ≥60% inhibition of RVFV infection at 3.12 µM compound concentration and ≥50% cell viability at 25 µM were considered hits. Of these, six compounds with high inhibitory activity were identified. In conclusion, the high-throughput assay could efficiently and safely identify several promising compounds that inhibited RVFV infection.

show abstract

Characterization of Clone 13, a Naturally Attenuated Avirulent Isolate of Rift Valley Fever Virus, which is Altered in the Small Segment *

Cited by 251 publications

References 0 publications

Molecular Epidemiology and Emergence of Rift Valley Fever

Molecular Epidemiology and Emergence of Rift Valley Fever

A Glycoprotein Subunit Vaccine Elicits a Strong Rift Valley Fever Virus Neutralizing Antibody Response in Sheep

High-Throughput Screening Using a Whole-Cell Virus Replication Reporter Gene Assay to Identify Inhibitory Compounds against Rift Valley Fever Virus Infection

Contact Info

Product

Resources

About